CSL Behring Medical Expert Portal is a global web portal designed for healthcare professionals (HCPs) outside the US who are interested in serious and life-threatening conditions. Register and login to access the information on this webpage and to receive updates when new content becomes available for your country. The medical and scientific information provided on this website is for informational purposes only and should not replace professional advice from a healthcare provider in your area. Product labels may vary from country to country. Please ensure to follow the applicable label for your country.

Disclaimer: Due to compliance regulations, not all content of this webpage is intended for UK healthcare practitioners. If you would like to access UK specific materials on this site, please reach out to your local CSL Behring medical representative (medinfo@cslbehring.com) for assistance.

Disclaimer

CSL EXPERT HIVE

Practice support

What would be your treatment of choice, and why?

Pathology:

CIDP
What would be your treatment of choice, and why?
 

As the proportions of patients demonstrating clinical improvement in CIDP is similar for IVIG1, SCIG2 and the FcRN inhibitor efgartigimod3, factors such as safety, patient preference and cost will be considerations in treatment choice.